Applied Markets
News on genetics and genomics applications in the Ag-Bio, Veterinary, Forensics, Food Safety, and Environmental Testing markets.
Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug
The company is enrolling up to 400 patients in its LIBRETTO-431 trial to evaluate survival and response to selpercatinib.